ISRCTN82391603已完成未知
Cardiovascular effects of empagliflozin in diabetes mellitus
niversity of Leeds0 个研究点目标入组 36 人开始时间: 2018年10月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
2021 Protocol article in https://pubmed.ncbi.nlm.nih.gov/34182806/ (added 13/08/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Type 2 diabetes mellitus
- •2. Metformin as single or dual therapy
- •3. Recent heart attack (<12 months)
- •4. HbA1c >48mmol/ml
- •5. 18-84 years old
- •6. Ability to provide informed consent
排除标准
- •1. Previous coronary artery bypass grafting (CABG)
- •2. Need for further revascularisation
- •3. Contra-indication to CMR scanning (some pacemakers, intraorbital debris, intraauricular implants, intracranial clips etc)
- •4. Contra-indication to Adenosine
- •5. Known allergy to contrast medium (gadolinium)
- •6. Renal dysfunction with eGFR< 60
- •7. Obesity where girth exceeds the scanner bore
- •8. Pregnancy or breastfeeding
- •9. Inability to lie flat for CMR scan
研究者
相似试验
Unknown
4 期
The Effects of Empagliflozin on Arterial Wall CharacteristicsVascular StiffnessHypoglycemic AgentsDiabetes ComplicationsDiabetes Mellitus, Type 1NCT03639545University Medical Centre Ljubljana120
尚未招募
4 期
Assessment of Empagliflozin effects in coronary artery diseaseIRCT20190412043247N2Zanjan University of Medical Sciences100
已完成
不适用
Effect of Empagliflozin on Endothelial Function in Cardiovascular High Risk Diabetes Mellitus: Multi-Center Placebo-Controlled Double-Blind Randomized TrialType 2 diabetes with high risk of cardiovascular diseaseJPRN-UMIN000024502Department of Cardiovascular Medicine, Saga University117
已完成
4 期
Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)Cardiovascular Risk FactorType 2 DiabetesNCT04183868University of Catanzaro26
已完成
4 期
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)Type2 DiabetesCardiovascular DiseasesNCT02973477University of Michigan45